Recombinant multi-species MRC2/CD280 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MRC2/CD280 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the mannose receptor family of proteins that contain a fibronectin type II domain and multiple C-type lectin-like domains. The encoded protein plays a role in extracellular matrix remodeling by mediating the internalization and lysosomal degradation of collagen ligands. Expression of this gene may play a role in the tumorigenesis and metastasis of several malignancies including breast cancer, gliomas and metastatic bone disease. [provided by RefSeq, Feb 2012]
The Alternative Names of target: C-type lectin domain family 13 member E,C-type mannose receptor 2,CD280,CLEC13E,ENDO180,Endo180,Endocytic receptor 180,MRC2,Macrophage mannose receptor 2,Mrc2,UPARAP,Urokinase receptor-associated protein),Urokinase-type plasminogen activator receptor-associated protein (UPAR-associated protein,mKIAA0709,uPARAP

Target products collectionGo to MRC2/CD280 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0222-Ag-1/ GM-Tg-hg-IP0222-Ag-2 Human MRC2/CD280 protein Human
GM-Tg-rg-IP0222-Ag-1/ GM-Tg-rg-IP0222-Ag-2 Rat MRC2/CD280 protein Rat
GM-Tg-mg-IP0222-Ag-1/ GM-Tg-mg-IP0222-Ag-2 Mouse MRC2/CD280 protein Mouse
GM-Tg-cynog-IP0222-Ag-1/ GM-Tg-cynog-IP0222-Ag-2 Cynomolgus/Rhesus macaque MRC2/CD280 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0222-Ag-1/ GM-Tg-felg-IP0222-Ag-2 Feline MRC2/CD280 protein Feline
GM-Tg-cang-IP0222-Ag-1/ GM-Tg-cang-IP0222-Ag-2 Canine MRC2/CD280 protein Canine
GM-Tg-bovg-IP0222-Ag-1/ GM-Tg-bovg-IP0222-Ag-2 Bovine MRC2/CD280 protein Bovine
GM-Tg-equg-IP0222-Ag-1/ GM-Tg-equg-IP0222-Ag-2 Equine MRC2/CD280 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0222-Ag-1/ GM-Tg-hg-IP0222-Ag-2; GM-Tg-rg-IP0222-Ag-1/ GM-Tg-rg-IP0222-Ag-2;
GM-Tg-mg-IP0222-Ag-1/ GM-Tg-mg-IP0222-Ag-2; GM-Tg-cynog-IP0222-Ag-1/ GM-Tg-cynog-IP0222-Ag-2;
GM-Tg-felg-IP0222-Ag-1/ GM-Tg-felg-IP0222-Ag-2; GM-Tg-cang-IP0222-Ag-1/ GM-Tg-cang-IP0222-Ag-2;
GM-Tg-bovg-IP0222-Ag-1/ GM-Tg-bovg-IP0222-Ag-2; GM-Tg-equg-IP0222-Ag-1/ GM-Tg-equg-IP0222-Ag-2
Products Name MRC2/CD280 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name MRC2/CD280
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MRC2/CD280 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.